Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loxapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.98 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.98 |
| ▸ | HRH1 | P35367 | 4/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.98 |
| ▸ | HRH2 | P25021 | 3/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.98 |
| ▸ | HTR1A | P08908 | 3/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.98 |
| ▸ | DRD1 | P21728 | 3/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxapine SCHEMBL30903930 | 1.00 | HRH4 (0.98) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL29374082 | 0.99 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL29482385 | 0.99 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL30324780 | 0.99 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL94146 | 0.99 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL19386241 | 0.99 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL4164270 | 0.98 | HRH4 (0.98) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL3674535 | 0.96 | HRH4 (0.95) | HRH4DRD2DRD4DRD3CHRM1 | |
| SCHEMBL7410631 | 0.90 | HRH4 (0.84) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL5500954 | 0.89 | LMNA (1.00) | HRH4DRD2DRD4DRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104825397-A | Controlled release delivery device containing organosol coating | ISA ODIDI | 2015-08-12 | — | — | CN | claimed |
| US-8524665-B2 | Use of secretin in treatments of disorders associated with the amygdala | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-09-03 | — | — | US | claimed |
| CN-102458543-A | Dry powder inhalers | 3M INNOVATIVE PROPERTIES CO | 2012-05-16 | — | — | CN | claimed |
| EP-2432535-A2 | DRY POWDER INHALERS | 3M Innovative Properties Company (US) | 2012-03-28 | — | — | EP | claimed |
| US-8088814-B2 | Administering a cyclooxygenase inhibitor; treating schizophrenia, delusional disorders, affective disorders, autism or tic disorders | MUELLER NORBERT (DE) | 2012-01-03 | — | — | US | claimed |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | MUELLER NORBERT | 2011-06-02 | — | — | US | claimed |
| WO-2010135340-A2 | DRY POWDER INHALERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-11-25 | — | — | WO | claimed |
| EP-1627639-B1 | Use of COX-2 inhibitors for the treatment of affective disorders | MUELLER NORBERT (DE) | 2009-12-23 | — | — | EP | claimed |
| EP-1414466-B1 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-08-19 | — | — | EP | claimed |
| CN-101453993-A | Controlled release delivery device containing organosol coating | ISA ODIDI (CA) | 2009-06-10 | — | — | CN | claimed |
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2003-07-10 | — | — | US | claimed |
| US-20030078246-A1 | Combinations for the treatment of inflammatory disorders | ZALICUS INC. | 2003-04-24 | — | — | US | claimed |
| WO-2003006026-A1 | COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-01-23 | — | — | WO | claimed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | claimed |
| US-6365178-B1 | DISSOLVING HYDROPHILIC SALT OF DRUG IN AQUEOUS DISPERSION OF HYDROPHOBIC PRESSURE SENSITIVE ADHESIVE, CASTING MIXTURE AND EVAPORATING WATER TO OBTAIN FILM, LAMINATING RELEASE LINER TO ONE SURFACE AND DRUG IMPERMEABLE BACKING LAYER TO OTHER | WATSON PHARMACEUTICALS, INC. | 2002-04-02 | — | — | US | claimed |
| EP-1117389-A1 | METHOD OF MAKING PRESSURE SENSITIVE ADHESIVE MATRIX PATCHES CONTAINING HYDROPHILIC SALTS OF DRUGS | TheraTech, Inc. (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000024386-A1 | METHOD OF MAKING PRESSURE SENSITIVE ADHESIVE MATRIX PATCHES CONTAINING HYDROPHILIC SALTS OF DRUGS | THERATECH, INC. (US) | 2000-05-04 | — | — | WO | claimed |
| US-5985317-A | POLYISOBUTYLENE; BACKING IMPERMEABLE TO DICLOFENAC SODIUM | THERATECH, INC. (US) | 1999-11-16 | — | — | US | claimed |
| EP-0952799-A1 | PRESSURE SENSITIVE ADHESIVE MATRIX PATCHES FOR TRANSDERMAL DELIVERY OF SALTS OF PHARMACEUTICAL AGENTS | THERATECH, INC. (US) | 1999-11-03 | — | — | EP | claimed |
| WO-1998009591-A1 | PRESSURE SENSITIVE ADHESIVE MATRIX PATCHES FOR TRANSDERMAL DELIVERY OF SALTS OF PHARMACEUTICAL AGENTS | THERATECH, INC. (US) | 1998-03-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | TPH2, MAOB, PTGS2 | DRD2 241/4885DRD4 819/4885DRD3 707/4885 |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | PTGES2, PTGER2, PTGDR2 | DRD2 15/4885DRD4 70/4885DRD3 141/4885 |
| US-20030078246-A1 | Combinations for the treatment of inflammatory disorders | IL6, FKBP1B, NR3C1 | DRD2 911/4885DRD4 880/4885DRD3 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.